
Repare Therapeutics Shifts Focus to Clinical Portfolio
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced a strategic shift to prioritize the development of its clinical-stage oncology programs. The company will concentrate on advancing its key programs—lunresertib, camonsertib, RP-1664, and RP-3467—while significantly reducing its preclinical…












